

Scott Ayton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4061397/publications.pdf>

Version: 2024-02-01

102
papers

8,859
citations

53660

45
h-index

46693

89
g-index

106
all docs

106
docs citations

106
times ranked

10613
citing authors

#	ARTICLE	IF	CITATIONS
1	Disruption of Hfe leads to skeletal muscle iron loading and reduction of hemoproteins involved in oxidative metabolism in a mouse model of hereditary hemochromatosis. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2022, 1866, 130082.	1.1	2
2	Selenium mediates exercise-induced adult neurogenesis and reverses learning deficits induced by hippocampal injury and aging. <i>Cell Metabolism</i> , 2022, 34, 408-423.e8.	7.2	58
3	Does the FDA-approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?. <i>Medical Journal of Australia</i> , 2022, , .	0.8	1
4	The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders. <i>Movement Disorders</i> , 2022, 37, 993-1003.	2.2	8
5	Thrombin induces ACSL4-dependent ferroptosis during cerebral ischemia/reperfusion. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 59.	7.1	88
6	Iron overload and impaired iron handling contribute to the dystrophic pathology in models of Duchenne muscular dystrophy. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1541-1553.	2.9	5
7	Ventricular enlargement caused by aducanumab. <i>Nature Reviews Neurology</i> , 2022, 18, 383-384.	4.9	6
8	Selective ferroptosis vulnerability due to familial Alzheimer's disease presenilin mutations. <i>Cell Death and Differentiation</i> , 2022, 29, 2123-2136.	5.0	32
9	Apolipoprotein E potently inhibits ferroptosis by blocking ferritinophagy. <i>Molecular Psychiatry</i> , 2022, , .	4.1	38
10	Ferroptosis promotes T-cell activation-induced neurodegeneration in multiple sclerosis. , 2022, 19, 913-924.		51
11	Ferroptosis and its potential role in the pathophysiology of Parkinson's Disease. <i>Progress in Neurobiology</i> , 2021, 196, 101890.	2.8	220
12	Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE ϵ 4, sex and age. <i>Progress in Neurobiology</i> , 2021, 198, 101904.	2.8	25
13	β -amyloid: The known unknowns. <i>Ageing Research Reviews</i> , 2021, 65, 101212.	5.0	27
14	The essential elements of Alzheimer's disease. <i>Journal of Biological Chemistry</i> , 2021, 296, 100105.	1.6	140
15	Unblinded by the light: amyloid-related imaging abnormalities in Alzheimer's clinical trials. <i>European Journal of Neurology</i> , 2021, 28, e1.	1.7	16
16	Iron accumulation in skeletal muscles of old mice is associated with impaired regeneration after ischaemia-reperfusion damage. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 476-492.	2.9	17
17	Zinc drives vasorelaxation by acting in sensory nerves, endothelium and smooth muscle. <i>Nature Communications</i> , 2021, 12, 3296.	5.8	25
18	Brain volume loss due to donanemab. <i>European Journal of Neurology</i> , 2021, 28, e67-e68.	1.7	20

#	ARTICLE	IF	CITATIONS
19	Iron reduces the propagation of pathological β -synuclein. <i>Journal of Neurochemistry</i> , 2021, 159, 414-416.	2.1	1
20	Ferroptosis as a mechanism of neurodegeneration in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2021, 159, 804-825.	2.1	89
21	Characterization of Selenium Compounds for Anti-ferroptotic Activity in Neuronal Cells and After Cerebral Ischemia-“Reperfusion Injury. <i>Neurotherapeutics</i> , 2021, 18, 2682-2691.	2.1	39
22	Copper and lipid metabolism: A reciprocal relationship. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021, 1865, 129979.	1.1	26
23	Regional brain iron associated with deterioration in Alzheimer's disease: A large cohort study and theoretical significance. <i>Alzheimer's and Dementia</i> , 2021, 17, 1244-1256.	0.4	71
24	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542 Td (edition	4.3	1,430
25	Ferroptosis and NRF2: an emerging battlefield in the neurodegeneration of Alzheimer's disease. <i>Essays in Biochemistry</i> , 2021, 65, 925-940.	2.1	57
26	Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology. <i>Molecular Psychiatry</i> , 2020, 25, 2932-2941.	4.1	202
27	Brain Zinc Deficiency Exacerbates Cognitive Decline in the R6/1 Model of Huntington's Disease. <i>Neurotherapeutics</i> , 2020, 17, 243-251.	2.1	15
28	Cu ^{II} (atm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease. <i>British Journal of Pharmacology</i> , 2020, 177, 656-667.	2.7	92
29	Fibrillar β -synuclein toxicity depends on functional lysosomes. <i>Journal of Biological Chemistry</i> , 2020, 295, 17497-17513.	1.6	30
30	Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that are impacted by APOE ϵ 4, sex and age but not pathology. <i>Alzheimer's and Dementia</i> , 2020, 16, e040745.	0.4	0
31	Deferiprone to delay dementia (the 3D trial). <i>Alzheimer's and Dementia</i> , 2020, 16, e044107.	0.4	8
32	Limited cerebral microbleeds effect on regional magnetic susceptibility measured by MRI. <i>Alzheimer's and Dementia</i> , 2020, 16, e044125.	0.4	0
33	Restricted Effect of Cerebral Microbleeds on Regional Magnetic Susceptibility. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 571-577.	1.2	6
34	Cerebrospinal fluid ceruloplasmin levels predict cognitive decline and brain atrophy in people with underlying β -amyloid pathology. <i>Neurobiology of Disease</i> , 2020, 139, 104810.	2.1	24
35	Amyloidogenic processing of Alzheimer's disease β -amyloid precursor protein induces cellular iron retention. <i>Molecular Psychiatry</i> , 2020, 25, 1958-1966.	4.1	52
36	Letter to the Editor. Hyperglycolysis as a common cause for elevated lactate in subarachnoid hemorrhage. <i>Journal of Neurosurgery</i> , 2020, , 1-2.	0.9	1

#	ARTICLE	IF	CITATIONS
37	Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis. <i>Breast Cancer Research</i> , 2019, 21, 94.	2.2	87
38	Cellular Senescence and Iron Dyshomeostasis in Alzheimer's Disease. <i>Pharmaceuticals</i> , 2019, 12, 93.	1.7	68
39	Decreasing iron neurotoxicity in pantothenate kinase-associated neurodegeneration. <i>Lancet Neurology</i> , The, 2019, 18, 616-617.	4.9	3
40	Mice overexpressing hepcidin suggest ferroportin does not play a major role in Mn homeostasis. <i>Metallomics</i> , 2019, 11, 959-967.	1.0	7
41	Zn-DTSM, A Zinc Ionophore with Therapeutic Potential for Acrodermatitis Enteropathica?. <i>Nutrients</i> , 2019, 11, 206.	1.7	1
42	Axonal dispatch of iron in neuronal signaling. <i>Nature Chemical Biology</i> , 2019, 15, 1135-1136.	3.9	6
43	Cerebrospinal fluid ferritin levels predict brain hypometabolism in people with underlying β 2-amyloid pathology. <i>Neurobiology of Disease</i> , 2019, 124, 335-339.	2.1	39
44	Treating Alzheimer's disease by targeting iron. <i>British Journal of Pharmacology</i> , 2019, 176, 3622-3635.	2.7	71
45	Parkinson's disease prevalence and the association with rurality and agricultural determinants. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 198-202.	1.1	13
46	Elevated plasma ferritin in elderly individuals with high neocortical amyloid- β 2 load. <i>Molecular Psychiatry</i> , 2018, 23, 1807-1812.	4.1	49
47	Evidence that iron accelerates Alzheimer's pathology: a CSF biomarker study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 456-460.	0.9	66
48	P2473: BRAIN IRON IS A CO-PATHOLOGY THAT IS STRONGLY ASSOCIATED WITH COGNITIVE DECLINE IN PEOPLE WITH ALZHEIMER'S PATHOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P904.	0.4	0
49	Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. <i>Advanced Materials</i> , 2018, 30, e1801362.	11.1	415
50	Current state of Alzheimer's fluid biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 821-853.	3.9	370
51	A Framework to Objectively Identify Reference Regions for Normalizing Quantitative Imaging. <i>Lecture Notes in Computer Science</i> , 2018, , 65-72.	1.0	1
52	More evidence is needed. Iron, incident cognitive decline and dementia: a systematic review. <i>Therapeutic Advances in Chronic Disease</i> , 2018, 9, 241-256.	1.1	14
53	Association of metals with the risk and clinical characteristics of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 117-121.	1.1	29
54	Marked Age-Related Changes in Brain Iron Homeostasis in Amyloid Protein Precursor Knockout Mice. <i>Neurotherapeutics</i> , 2018, 15, 1055-1062.	2.1	53

#	ARTICLE	IF	CITATIONS
55	Iron and Alzheimer's Disease: An Update on Emerging Mechanisms. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S379-S395.	1.2	205
56	Ferroptosis and cell death mechanisms in Parkinson's disease. <i>Neurochemistry International</i> , 2017, 104, 34-48.	1.9	260
57	Evidence of a Cardiovascular Function for Microtubule-Associated Protein Tau. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 849-860.	1.2	23
58	Association of Cerebrospinal Fluid Ferritin Level With Preclinical Cognitive Decline in <i>APOE</i> ϵ ₄ Carriers. <i>JAMA Neurology</i> , 2017, 74, 122.	4.5	61
59	Nanoscale Imaging Reveals Big Role for Iron in Alzheimer's Disease. <i>Cell Chemical Biology</i> , 2017, 24, 1192-1194.	2.5	13
60	Tau-mediated iron export prevents ferroptotic damage after ischemic stroke. <i>Molecular Psychiatry</i> , 2017, 22, 1520-1530.	4.1	449
61	A normalisation framework for quantitative brain imaging; application to quantitative susceptibility mapping. , 2017, , .		3
62	The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2017, 5, 53.	2.4	77
63	Lithium suppression of tau induces brain iron accumulation and neurodegeneration. <i>Molecular Psychiatry</i> , 2017, 22, 396-406.	4.1	66
64	[P3 ¹⁵³]: THE INFLUENCE OF AMYLOID β PRECURSOR PROTEIN PROTEOLYTIC PROCESSING ON NEURONAL IRON HOMEOSTASIS. <i>Alzheimer's and Dementia</i> , 2017, 13, P993.	0.4	0
65	[P1 ⁴⁴⁴]: QUANTITATIVE SUSCEPTIBILITY MAPPING OF THE HIPPOCAMPUS PREDICTS HIPPOCAMPAL ATROPHY IN A β ²⁺ ELDERLY CONTROLS AND ALZHEIMER'S DISEASE PATIENTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P454.	0.4	2
66	Cerebral quantitative susceptibility mapping predicts amyloid- β -related cognitive decline. <i>Brain</i> , 2017, 140, 2112-2119.	3.7	213
67	Targeting Transition Metals for Neuroprotection in Alzheimer's Disease. , 2017, , 193-215.		2
68	S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency. <i>Journal of Clinical Investigation</i> , 2017, 127, 4365-4378.	3.9	62
69	Transferrin protects against Parkinsonian neurotoxicity and is deficient in Parkinson's substantia nigra. <i>Signal Transduction and Targeted Therapy</i> , 2016, 1, 16015.	7.1	36
70	O5 ⁰⁵⁰¹ : CSF Ferritin Determines the Risk of Cognitive Decline in Preclinical <i>APOE</i> ϵ ₄ Carriers. <i>Alzheimer's and Dementia</i> , 2016, 12, P387.	0.4	0
71	The Complex Role of Apolipoprotein E in Alzheimer's Disease: an Overview and Update. <i>Journal of Molecular Neuroscience</i> , 2016, 60, 325-335.	1.1	64
72	Type I interferons contribute to the neuroinflammatory response and disease progression of the MPTP mouse model of Parkinson's disease. <i>Glia</i> , 2016, 64, 1590-1604.	2.5	71

#	ARTICLE	IF	CITATIONS
73	Metal-Protein Attenuating Compounds in Neurodegenerative Diseases. , 2016, , .		0
74	Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias. <i>Movement Disorders</i> , 2015, 30, 796-804.	2.2	32
75	Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. <i>Nature Communications</i> , 2015, 6, 6760.	5.8	240
76	Parkinson's Disease Iron Deposition Caused by Nitric Oxide-Induced Loss of β 2-Amyloid Precursor Protein. <i>Journal of Neuroscience</i> , 2015, 35, 3591-3597.	1.7	109
77	Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse. <i>Neurobiology of Disease</i> , 2015, 81, 168-175.	2.1	73
78	Enduring Elevations of Hippocampal Amyloid Precursor Protein and Iron Are Features of β 2-Amyloid Toxicity and Are Mediated by Tau. <i>Neurotherapeutics</i> , 2015, 12, 862-873.	2.1	50
79	Biometals and Their Therapeutic Implications in Alzheimer's Disease. <i>Neurotherapeutics</i> , 2015, 12, 109-120.	2.1	109
80	Increased Ndfip1 in the Substantia Nigra of Parkinsonian Brains Is Associated with Elevated Iron Levels. <i>PLoS ONE</i> , 2014, 9, e87119.	1.1	28
81	Nigral Iron Elevation Is an Invariable Feature of Parkinson's Disease and Is a Sufficient Cause of Neurodegeneration. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	126
82	P4-253: EVIDENCE FOR APOE PROTECTING AGAINST BRAIN IRON OVERLOAD. , 2014, 10, P878-P878.		1
83	An iron-dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta. <i>Chemical Science</i> , 2014, 5, 2160-2169.	3.7	98
84	A comparison of ceruloplasmin to biological polyanions in promoting the oxidation of Fe ²⁺ under physiologically relevant conditions. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2014, 1840, 3299-3310.	1.1	24
85	Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: implications for Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2014, 9, 27.	4.4	60
86	Motor and cognitive deficits in aged tau knockout mice in two background strains. <i>Molecular Neurodegeneration</i> , 2014, 9, 29.	4.4	117
87	Ceruloplasmin and β 2-amyloid precursor protein confer neuroprotection in traumatic brain injury and lower neuronal iron. <i>Free Radical Biology and Medicine</i> , 2014, 69, 331-337.	1.3	49
88	P4-369: REVISITING THE ALZHEIMER'S AND PARKINSONISM PHENOTYPES OF TAU KO MICE: POTENTIAL GENETIC BACKGROUND EFFECT. , 2014, 10, P924-P924.		0
89	Metallostasis in Alzheimer's disease. <i>Free Radical Biology and Medicine</i> , 2013, 62, 76-89.	1.3	297
90	Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. <i>Annals of Neurology</i> , 2013, 73, 554-559.	2.8	218

#	ARTICLE	IF	CITATIONS
91	The effect of dopamine on MPTP-induced rotarod disability. <i>Neuroscience Letters</i> , 2013, 543, 105-109.	1.0	25
92	Amine oxidase activity of β -amyloid precursor protein modulates systemic and local catecholamine levels. <i>Molecular Psychiatry</i> , 2013, 18, 245-254.	4.1	14
93	A delicate balance: Iron metabolism and diseases of the brain. <i>Frontiers in Aging Neuroscience</i> , 2013, 5, 34.	1.7	314
94	Zinc in Alzheimer's and Parkinson's Diseases. , 2013, , 2433-2441.		0
95	The A β -Induced NFAT Apoptotic Pathway Is Also Activated by GSK-3 Inhibition: Implications for Alzheimer Therapeutics. <i>Journal of Neuroscience</i> , 2012, 32, 9454-9456.	1.7	6
96	PBT2 Reduces Toxicity in a <i>C. elegans</i> Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2012, 1, 211-219.	0.9	57
97	The hypoxia imaging agent Cull(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease. <i>Journal of Experimental Medicine</i> , 2012, 209, 837-854.	4.2	151
98	Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. <i>Nature Medicine</i> , 2012, 18, 291-295.	15.2	491
99	GSK-3 in Neurodegenerative Diseases. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-9.	1.1	119
100	β -Synuclein Transgenic Mice Reveal Compensatory Increases in Parkinson's Disease-Associated Proteins DJ-1 and Parkin and Have Enhanced β -Synuclein and PINK1 Levels After Rotenone Treatment. <i>Journal of Molecular Neuroscience</i> , 2010, 42, 243-254.	1.1	37
101	Tau protein: Relevance to Parkinson's disease. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 1775-1778.	1.2	180
102	Serotonergic lesions of the dorsal hippocampus differentially modulate locomotor hyperactivity induced by drugs of abuse in rats: implications for schizophrenia. <i>Psychopharmacology</i> , 2009, 206, 665-676.	1.5	10